Improved patency and reduced intimal hyperplasia in PTFE grafts with luminal immobilized heparin compared with standard PTFE grafts at six months in a sheep model

Journal of Cardiovascular Surgery

Volumn 51, Issue 3, 2010, Pages 443-448

  Pedersen, G ^a,b   Laxdal, E ^b,c,e   Ellensen, V ^a,b   Jonung, T ^b   Mattsson, E ^d  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Hyperplasia; Polytetrafluoroethylene; Transplantation

Indexed keywords

HEPARIN; ANTICOAGULANT AGENT; BIOMATERIAL; POLITEF;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY BYPASS; ARTERY INTIMA PROLIFERATION; ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GRAFT OCCLUSION; GRAFT PATENCY; MATERIAL COATING; MORPHOMETRICS; NONHUMAN; POLITEF IMPLANT; SHEEP; THICKNESS; ANIMAL; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL TRANSPLANTATION; COMPARATIVE STUDY; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; INTIMA; PATHOLOGY; PATHOPHYSIOLOGY; PROSTHESIS; SURGERY; TIME; VASCULAR PATENCY;

ANIMALS; ANTICOAGULANTS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CAROTID ARTERY, COMMON; COATED MATERIALS, BIOCOMPATIBLE; FEMALE; GRAFT OCCLUSION, VASCULAR; HEPARIN; HYPERPLASIA; MODELS, ANIMAL; POLYTETRAFLUOROETHYLENE; PROSTHESIS DESIGN; SHEEP; TIME FACTORS; TUNICA INTIMA; VASCULAR PATENCY;

EID: 77955378395     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Klinkert P, Schepers A, Burger DH, Van Bocket JH, Breslau PJ. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. J Vasc Surg 2003;37:149-55.
2. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gallhagen A. Improvements in GORE-TEX vascular graft performance by Carmeda BioActive surface heparin immobilization. Eur J Vasc Endovasc Surg 2003;25:432-7.
3. Lin PH, Chen C, Bush RL, Yao Q, Lumsden AB, Hanson SR. Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model. J Vasc Surg 2004;39:1322-8.
4. Bosiers M, Deloose K, Verbist J, Schroë H, Lauwers G, Lansink W et al. Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. J Vasc Surg 2006;43:313-8.
5. Peeters P, Verbist J, Deloose K, Bosiers M. Results with heparin bonded polytetrafluoroethylene grafts for femorodistal bypasses. J Cardiovasc Surg (Torino) 2006;47:407-13.
6. Walluscheck KP, Bierkandt S, Brandtt M, Cremer J. Infrainguinal ePTFE vascular graft with bioactive surface heparin bonding. First clinical results. J Cardiovasc Surg (Torino) 2005;46:425-30.
7. Edmondson RA, Cohen AT, Das SK, Wagner MB, Kakkar W. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994;344:914-8.
8. Dryjski M, Mikata E, Bjornsson TD. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid. J Vasc Surg 1988;8:623-33.
9. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol 2000;190:300-9.
10. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977;265:625-6.
11. Ao PY, Hawthorne WJ, Taylor DA, Fletcher JP. Optimal dose and duration of heparin for inhibition of intimal hyperplasia. Int Angiol 1997;16:94-100.
12. Ao PY, Hawthorne WJ, Coombs R, Fletcher JP. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model. Int Angiol 1999;18:131-9.
13. Fletcher JP, Ao PY, Hawthorne WJ. Antiproliferative effects of low molecular weight heparin. ANZ J Surg 2004;74:793-6.
14. Simoni G, Galleano R, Civalleri D, Decian F, Desalvo P, Ceppa P et al. Pharmacological control of intimal hyperplasia in small diameter polytetrafluoroethylene grafts. An experimental study. Int Angiol 1996;15:50-6.
15. Borowiec J, Thelin S, Bagge L, Nilsson L, Venge P, Hansson HE. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. J Thorac Cardiovasc Surg 1992;104:642-7.
16. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998;352:673-81.
17. Kocsis JF, Llanos G, Holmer E. Heparin-coated stents. J Long Term Eff Med Implants 2000;10:19-45.
18. Riesenfeld J, Ries D, Hetzer R. Analysis of the heparin coating of an EXCOR Ventricular Assist Device after 855 days in a patient. Abstract No 180. Presented at the 32nd Society for Biomaterials Annual Meeting, Chicago, IL; 2007 18-21 April.
19. Dorffler-Melly J, Koopman MM, Adam DJ, Buller HR, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2003; CD000535.
20. Adam DJ. Antiplatelet and anticoagulant therapy to prevent bypass graft thrombosis in patients with lower extremity arterial occlusive disease. Int Angiol 2001;20:90-8.
21. Heyligers JM, Lisman T, Verhagen HJ, Weeterings C, Degroot PG, Moll FL. A heparin-bonded vascular graft generates no systemic effect on markers of hemostasis activation or detectable heparin-induced thrombocytopenia-associated antibodies in humans. J Vasc Surg 2008;47:324-9.